Ashvin Patel
Research Subjects
Ashvin Patel has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Armen Khachatryan
The Disc Replacement Center, South Jordan, UT
2 shared publications - Rick C. Sasso
Indiana Spine Group, Carmel, IN
2 shared publications - Adam Bruggeman
Texas Spine Care Center, San Antonio, TX
1 shared publication - Amir Vokshoor
Institute of Neuro Innovation, Santa Monica, CA
1 shared publication - Andrew Park
Texas Spine Consultants, Addison, TX
1 shared publication - Christopher R. Good
Virginia Spine Institute, Reston, VA
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Wolters Kluwer Health in Spine Open
- Vol. 2 (4)
Superior Outcomes for a Novel Cervical Disc Replacement Compared With Anterior Cervical Discectomy and Fusion: Two-Year Results from a Prospective IDE Study With Propensity-Matched Historical Control
Study Design: Prospective, multicenter, study with a propensity-matched historical control conducted under a US FDA IDE. Objective: To evaluate the safety and efficacy of the synergy disc (SD) compared to anterior cervical discectomy and fusion (ACDF) for single-level symptomatic cervical disc disease. Summary of Background Data: Cervical disc replacement (CDR) was developed to preserve motion while achieving outcomes comparable to ACDF. Although currently available devices are designed primarily to maintain motion, the SD is designed to provide intentional motion and restore segmental lordosis to help optimize sagittal balance. The disc is composed of titanium endplates that articulate with an ultra-high molecular weight polyethylene core with either 0 or 6° of lordosis. Materials and Methods: Adults with cervical radiculopathy or myelopathy at a single level and qualifying pain (VAS) and disability scores (NDI) were enrolled. The primary study endpoint was individual composite clinical success (CCS) at 24 months. CCS was achieved if a subject met the following criteria: at least a 15-point improvement in NDI score, maintenance/improvement in neurological status, and absence of the following: secondary surgical intervention on the index level, radiographic failure, and device-related serious adverse events. Secondary endpoints include change from baseline on patient-reported outcomes and treatment satisfaction. Results: One hundred seventy-seven patients were enrolled in the CDR group across 20 US sites; data on 192 control subjects were available. The study achieved success for both noninferiority and superiority at the two-year primary endpoint ( P <0.0001). At two years, 87.1% in the CDR group and 56.6% in the control group met CCS success. The CDR group demonstrated greater improvements in pain and function across all time points. Significant increases in segmental and regional alignment were observed in the CDR group. Conclusions: Two-year primary endpoint results support the safety and efficacy of a CDR that incorporates motion and lordosis. Clinical success results were superior to ACDF.
- 23 September 2026
- Published by Wolters Kluwer Health in Spine Open
- Vol. 2 (4)
Open AccessSuperior Outcomes for a Novel Cervical Disc Replacement Compared With Anterior Cervical Discectomy and Fusion: Two-Year Results from a Prospective IDE Study With Propensity-Matched Historical Control
Study Design: Prospective, multicenter, study with a propensity-matched historical control conducted under a US FDA IDE. Objective: To evaluate the safety and efficacy of the synergy disc (SD) compared to anterior cervical discectomy and fusion (ACDF) for single-level symptomatic cervical disc disease. Summary of Background Data: Cervical disc replacement (CDR) was developed to preserve motion while achieving outcomes comparable to ACDF. Although currently available devices are designed primarily to maintain motion, the SD is designed to provide intentional motion and restore segmental lordosis to help optimize sagittal balance. The disc is composed of titanium endplates that articulate with an ultra-high molecular weight polyethylene core with either 0 or 6° of lordosis. Materials and Methods: Adults with cervical radiculopathy or myelopathy at a single level and qualifying pain (VAS) and disability scores (NDI) were enrolled. The primary study endpoint was individual composite clinical success (CCS) at 24 months. CCS was achieved if a subject met the following criteria: at least a 15-point improvement in NDI score, maintenance/improvement in neurological status, and absence of the following: secondary surgical intervention on the index level, radiographic failure, and device-related serious adverse events. Secondary endpoints include change from baseline on patient-reported outcomes and treatment satisfaction. Results: One hundred seventy-seven patients were enrolled in the CDR group across 20 US sites; data on 192 control subjects were available. The study achieved success for both noninferiority and superiority at the two-year primary endpoint ( P <0.0001). At two years, 87.1% in the CDR group and 56.6% in the control group met CCS success. The CDR group demonstrated greater improvements in pain and function across all time points. Significant increases in segmental and regional alignment were observed in the CDR group. Conclusions: Two-year primary endpoint results support the safety and efficacy of a CDR that incorporates motion and lordosis. Clinical success results were superior to ACDF.
- Open Access
- 27 February 2026
- Published by Wolters Kluwer Health in Spine
- Vol. 51 (14) , 975-986
Prospective, Multicenter Study of Two-Level Cervical Arthroplasty With a PEEK-On-Ceramic Cervical Total Disc Replacement
Study Design.: Prospective, nonrandomized cohort analysis. Objective.: To evaluate five-year outcomes of patients treated with a polyetheretherketone (PEEK)-on-ceramic cTDR device at two levels for radiculopathy and/or myelopathy. Background.: Cervical total disc replacement (cTDR) has gained acceptance as a treatment for symptomatic cervical degenerative disc disease (DDD). Long-term follow-up studies are required to further assess clinical and radiographic outcomes, specifically for patients treated at two consecutive levels. Methods.: Patients implanted with Simplify Cervical Disc at two levels from C3 to 7 as part of a Food and Drug Administration investigational device exemption trial (NCT03123549) were contacted, consented, and prospectively followed from 36 to 60 months. Results.: Of 181 patients treated, 80% (144) completed five-year follow-up. Composite clinical success was 86% at 60 months versus 88% at 24 months. At 60 months, 95% had a minimum 15-point improvement in Neck Disability Index compared with 93% at 24 months. Mean neck pain improvement at 24 months (-6.1 on a 10-point numeric scale) was maintained at 60 months. Similarly, improvements in arm pain scores were also maintained from −5.7 at 24 months to −6.2 at 60 months. The cumulative five-year index level reoperation rate was 5% (1%/year) and the adjacent level reoperation rate was 2.2% (0.4%/year). Segmental range of motion was maintained at both operated segments through five years, with an average of 9.0° at superior and 8.7° at inferior levels. Bridging bone was identified in 1% of both the superior and inferior levels, 6% of superior levels only, and 6% of inferior levels only. Conclusions.: This intermediate five-year follow-up study augments previously reported two-year results, supporting that the Simplify cTDR is safe and effective for the treatment of two-level symptomatic cervical DDD. Statistically significant improvements in pain and disability at two-year postoperative were maintained or improved at five years with preservation of motion and low reoperation rates at index and adjacent levels.
- 27 February 2026
- Published by Wolters Kluwer Health in Spine
- Vol. 51 (14) , 975-986
Open AccessProspective, Multicenter Study of Two-Level Cervical Arthroplasty With a PEEK-On-Ceramic Cervical Total Disc Replacement
Study Design.: Prospective, nonrandomized cohort analysis. Objective.: To evaluate five-year outcomes of patients treated with a polyetheretherketone (PEEK)-on-ceramic cTDR device at two levels for radiculopathy and/or myelopathy. Background.: Cervical total disc replacement (cTDR) has gained acceptance as a treatment for symptomatic cervical degenerative disc disease (DDD). Long-term follow-up studies are required to further assess clinical and radiographic outcomes, specifically for patients treated at two consecutive levels. Methods.: Patients implanted with Simplify Cervical Disc at two levels from C3 to 7 as part of a Food and Drug Administration investigational device exemption trial (NCT03123549) were contacted, consented, and prospectively followed from 36 to 60 months. Results.: Of 181 patients treated, 80% (144) completed five-year follow-up. Composite clinical success was 86% at 60 months versus 88% at 24 months. At 60 months, 95% had a minimum 15-point improvement in Neck Disability Index compared with 93% at 24 months. Mean neck pain improvement at 24 months (-6.1 on a 10-point numeric scale) was maintained at 60 months. Similarly, improvements in arm pain scores were also maintained from −5.7 at 24 months to −6.2 at 60 months. The cumulative five-year index level reoperation rate was 5% (1%/year) and the adjacent level reoperation rate was 2.2% (0.4%/year). Segmental range of motion was maintained at both operated segments through five years, with an average of 9.0° at superior and 8.7° at inferior levels. Bridging bone was identified in 1% of both the superior and inferior levels, 6% of superior levels only, and 6% of inferior levels only. Conclusions.: This intermediate five-year follow-up study augments previously reported two-year results, supporting that the Simplify cTDR is safe and effective for the treatment of two-level symptomatic cervical DDD. Statistically significant improvements in pain and disability at two-year postoperative were maintained or improved at five years with preservation of motion and low reoperation rates at index and adjacent levels.